Taken together, these findings suggest that incretin related agents, including GLP-1 analogues, are useful therapeutic tools for type 2 diabetes mellitus and may ameliorate the risk of bone fracture in these patients. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.